Skip to Main content Skip to Navigation
Master Thesis

Effets indésirables du Levothyrox® nouvelle formule : l’hypothèse d’un effet nocebo est-elle acceptée par les médecins généralistes ?

Abstract : INTRODUCTION. In Marsh 2017, the change of formulation of pharmaceutical form of Levothyrox has induced a large controversy in France. Concerned learned societies suggest a nocebo effect hypothesis. The main aim of this study is to evaluate whether general practitioners in Isère accept the hypothesis of a nocebo effect to explain the adverse effects of the new formulation of Levothyrox. METHOD. This descriptive study was conducted through an online self-administered questionnaire sent to all liberal general practitioners in Isère. RESULTS. Data provided by 104 questionnaires were analyzed. Ninety-six percent of physicians reported complaints after the introduction of the new formulation. Eighty-four percent of physicians accepted nocebo effect hypothesis. Seventy-two percent of practitioners reported that they often noted more complaints after the media coverage. The occurrence of adverse events mainly involved in psychologically fragile patients. The management of this crisis by the authorities was generally insufficient (56.7%). CONCLUSION. To objectively confirm or deny the hypothesis of a nocebo effect of the new formulation of levothyrox, it would be necessary to carry out a prospective double-blind comparative study. However, our study shows that the majority of general practitioners in Isère accept the hypothesis that a nocebo effect is possible. This shows that, if indeed it is a nocebo effect, general practitioners could have played a key role in limiting this crisis, subject to better communication between the ANSM, the Merck laboratory, general practitioners. Our study thus gives keys to limit any future crises.
Document type :
Master Thesis
Complete list of metadatas

Cited literature [18 references]  Display  Hide  Download

https://dumas.ccsd.cnrs.fr/dumas-01897023
Contributor : Jean-Hugues Morneau <>
Submitted on : Wednesday, October 17, 2018 - 4:27:34 PM
Last modification on : Wednesday, July 15, 2020 - 8:58:04 AM
Long-term archiving on: : Friday, January 18, 2019 - 12:52:45 PM

File

2018GREA5119_erciyas_aytekin(1...
Files produced by the author(s)

Identifiers

  • HAL Id : dumas-01897023, version 1

Citation

Aytekin Erciyas. Effets indésirables du Levothyrox® nouvelle formule : l’hypothèse d’un effet nocebo est-elle acceptée par les médecins généralistes ?. Médecine humaine et pathologie. 2018. ⟨dumas-01897023⟩

Share

Metrics

Record views

203

Files downloads

204